Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis.
Molecular cancer therapeutics (2003) - Comments
pubmed: 14617792 

Ali R Jazirehi, Xiao-Hu Gan, Sven De Vos, Christos Emmanouilides, Benjamin Bonavida